RT Journal Article
SR Electronic
T1 595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A677
OP A677
DO 10.1136/jitc-2023-SITC2023.0595
VO 11
IS Suppl 1
A1 Forster, Martin
A1 Felip, Enriqueta
A1 Majem, Margarita
A1 Doger, Bernard
A1 Clay, Tim
A1 Carcereny, Enric
A1 Bondarenko, Igor
A1 Peguero, Julio
A1 Dols, Manuel Cobo
A1 Ursol, Grygorii
A1 Kalinka, Ewa
A1 Ledo, Gema Garcia
A1 Martinez, Laia Vilà
A1 Krebs, Matthew
A1 Iams, Wade T
A1 Mueller, Christian
A1 Brignone, Chrystelle
A1 Triebel, Frederic
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A677.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.